Efficacy and safty of high dose blood purification for hepatic encephalopathy by acute liver failure and fluminant hepatitis

Efficacy and safty of high dose blood purification for hepatic encephalopathy by acute liver failure and fluminant hepatitis - Efficacy and safty of high dose blood purification for hepatic encephalopathy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016672

Enrollment

Registered

2015-10-16

Start date

2014-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic encephalopathy

Interventions

High dose blood purification by on-line HDF and/or high flow - high volume CHDF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hepatic encephalopathy by acute hepatic failure or fluminant hepatitis 2. Candidate of recipient of liver transplantation 3. Written agreement after informed consent

Exclusion criteria

Exclusion criteria: 1. Postoperative liver failure without liver transplantation 2. Dinied liver transplantation 3. Unccontrolled gastrointestinal bleeding 4. Unconsciousnes by other causes 5. Improper patients

Design outcomes

Primary

Measure	Time frame
progression-free survival	—

Countries

Japan

Contacts

Public ContactTatsuo Tsukamoto

Kyoto University Hospital Nephrology

ttsukamo@kuhp.kyoto-u.ac.jp075-751-3860

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026